SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QIAGEN (QGENF) - Star of Germany's Biotechs

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: JakeStraw6/28/2006 9:22:13 AM
   of 122
 
QIAGEN Announces its Inclusion in the New NASDAQ Global Select Market
biz.yahoo.com
Wednesday June 28, 9:00 am ET

The Market With the Highest Initial Listing Standards in the World

VENLO, The Netherlands, June 28 /PRNewswire-FirstCall/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA), the world's leading provider of preanalytical sample preparation products enabling genetic and protein analysis today announced that it will be included in the new NASDAQ Global Select Market. The NASDAQ Global Select Market is reported to have the highest initial listing standards of any exchange in the world based on financial and liquidity requirements. Prior to the change, QIAGEN's shares have been listed on the NASDAQ National Market. QIAGEN's shares will continue to be traded under the ticker QGEN on the NASDAQ Global Select Market and under the ticker QIA and the WKN 901626 on the Prime Standard segment of the Frankfurt Stock Exchange.

NASDAQ has announced that beginning July 3, NASDAQ-listed companies will be classified under three listing tiers - NASDAQ Global Select Market, NASDAQ Global Market, and NASDAQ Capital Market. NASDAQ also plans to launch indexes based on these new tiers.

QIAGEN's common shares have been listed on NASDAQ since the Company's initial public offering in 1996. In 1997 QIAGEN also listed its common shares on the Frankfurt Stock Exchange where the shares are today traded in the Prime Segment. On both exchanges combined, QIAGEN's shares recorded an average number of shares traded per day of approximately one million over the last six months.

"We are very pleased that our common shares were accepted for trading on the new NASDAQ Global Select Market. This reflects our ongoing commitment to increase QIAGEN's value and visibility," said Roland Sackers, QIAGEN's Chief Financial Officer. "We are convinced that the decision by the NASDAQ to create a new market which accepts only companies which meet highest listing standards in the world, with measures including market value, liquidity and earnings, is the right move to further increase the attractiveness of this trading platform."

"QIAGEN is an example of an industry leader that has achieved superior listing standards, which clearly defines the essence of the NASDAQ Global Select Market," said Bruce Aust, Executive Vice President, Corporate Client Group. "NASDAQ is focused on leading a race to the top in terms of listing qualifications. In recognizing these companies, we are highlighting their achievement in meeting the requirements to be included in the market with the highest listing standards in the world," added Mr. Aust.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext